

CANCER GENETICS, INC  
Form 8-K  
June 11, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): June 5, 2013**

**CANCER GENETICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
  
of Incorporation)

**001-35817**  
(Commission  
  
File Number)

**04-3462475**  
(IRS Employer  
  
Identification No.)

Edgar Filing: CANCER GENETICS, INC - Form 8-K

**201 Route 17 North 2<sup>nd</sup> Floor, Rutherford, New Jersey**  
**(Address of Principal Executive Offices)**  
**Registrant's telephone number, including area code (201) 528-9200**

**07070**  
**(Zip Code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On June 5, 2013, the compensation committee of the board of directors of Cancer Genetics, Inc. (the Company) made its final determinations with respect to the 2012 bonus awards for Panna Sharma, the Company's Chief Executive Officer, Elizabeth Czerepak, the Company's Chief Financial Officer and Jane Holdsworth, the Company's Vice President Research and Development, as follows: Mr. Sharma - \$150,000, Ms. Czerepak - \$75,000, and Dr. Holdsworth - \$40,000. The Compensation Committee also confirmed bonuses in relation to completion of the Company's April 2013 initial public offering to Mr. Sharma of \$90,000 and to Ms. Czerepak of \$45,000, and granted the Company's Chairman of the Board, Dr. Raju S. K. Chaganti, a bonus of \$50,000 for his leadership and advancing the Company's technology.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CANCER GENETICS, INC.**

By: /s/ Elizabeth A. Czerepak  
Name: Elizabeth A. Czerepak  
Title: Chief Financial Officer

Date: June 11, 2013